Cargando…
Benefits of Renin-Angiotensin Blockade on Retinopathy in Type 1 Diabetes Vary With Glycemic Control
OBJECTIVE: Optimal glycemic control slows diabetic retinopathy (DR) development and progression and is the standard of care for type 1 diabetes. However, these glycemic goals are difficult to achieve and sustain in clinical practice. The Renin Angiotensin System Study (RASS) showed that renin-angiot...
Autores principales: | Harindhanavudhi, Tasma, Mauer, Michael, Klein, Ronald, Zinman, Bernard, Sinaiko, Alan, Caramori, M. Luiza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142059/ https://www.ncbi.nlm.nih.gov/pubmed/21715517 http://dx.doi.org/10.2337/dc11-0476 |
Ejemplares similares
-
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
por: Ravid, Mordchai
Publicado: (2009) -
Renin–angiotensin system blockade for the risk of cancer and death
por: Shen, Jian, et al.
Publicado: (2016) -
Management of proteinuria: blockade of the renin–angiotensin–aldosterone system
por: Athavale, Akshay, et al.
Publicado: (2020) -
Left ventricular hypertrophy and renin-angiotensin system blockade
por: Cowan, Brett R., et al.
Publicado: (2009) -
Renin–angiotensin system blockade in the COVID-19 pandemic
por: Cohen, Jordana B, et al.
Publicado: (2021)